Literature DB >> 6893156

Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.

J A Green, A A Dawson, L F Fell, S Murray.   

Abstract

The dose of combination chemotherapy in Hodgkin's disease is commonly calculated from a formula based on the body surface area. A method is described for measuring the intensity of combination chemotherapy actually received compared to the calculated planned dose. The technique is applied to 56 patients receiving mustine, vinblastine, procarbazine and prednisolone, but would also be suitable for other cytotoxic regimens. The planned dosage intensity had to be significantly reduced in over half of the patients because of marrow toxicity. Splenectomized patients received a higher dose intensity than those in whom the procedure was not performed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6893156      PMCID: PMC1429958          DOI: 10.1111/j.1365-2125.1980.tb05847.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Infections in patients with malignant lymphoma treated with combination chemotherapy.

Authors:  R Feld; G P Bodey
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

2.  Causes of death in patients with malignant lymphoma.

Authors:  R Feld; G P Bodey; V Rodriguez; M Luna
Journal:  Am J Med Sci       Date:  1974-08       Impact factor: 2.378

3.  Combination chemotherapy in advanced and recurrent Hodgkin's disease.

Authors:  T J McElwain; P F Wrigley; A Hunter; D Crowther; J S Malpas; M J Peckham; D W Smithers; G H Fairley
Journal:  Natl Cancer Inst Monogr       Date:  1973-05

4.  Splenectomy effects on chemotherapy in Hodgkin's disease.

Authors:  F Panettiere; C A Coltman
Journal:  Arch Intern Med       Date:  1973-03

5.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

6.  Combination chemotherapy in generalized Hodgkin's disease.

Authors:  W M Nicholson; M E Beard; D Crowther; A G Stansfeld; C P Vartan; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1970-07-04

7.  Tolerance to chemotherapy after prior irradiation for Hodgkin's disease.

Authors:  R E Curran; R E Johnson
Journal:  Ann Intern Med       Date:  1970-04       Impact factor: 25.391

8.  Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma.

Authors:  D C Ihde; V T DeVita; G P Canellos; R C Young
Journal:  Blood       Date:  1976-02       Impact factor: 22.113

  8 in total
  7 in total

1.  Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting.

Authors:  Ilanit Shalom-Sharabi; Ofer Lavie; Noah Samuels; Lital Keinan-Boker; Efraim Lev; Eran Ben-Arye
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-20       Impact factor: 4.553

2.  Evaluation of systemic chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin for advanced bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.

Authors:  T Kotake; H Akaza; S Isaka; S Kagawa; K Koiso; T Machida; A Maru; Y Matsumura; I Miyagawa; T Niijima
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging.

Authors:  H Sato; K Sugiyama; M Hoshi; M Urushiyama; K Ishizuka
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

4.  Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.

Authors:  P Lagarde; F Bonichon; H Eghbali; I de Mascarel; J Chauvergne; B Hoerni
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

5.  Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.

Authors:  Antonio Gutiérrez; Leyre Bento; Antonia Maria Bautista-Gili; Francesc Garcia; Jordi Martinez-Serra; Blanca Sanchez; Clara Martorell; Jordi Gines; Lucia Garcia; Eva Gimeno; Mariana Ferraro; Raquel Del Campo; Joan Bargay; Albert Perez; Javier Vercher; Miguel Scaff; Ana Pacheco; Carmen Ballester; Florencia Garcia; Rafael Ramos; Antonio Salar; Joan Besalduch
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

6.  A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.

Authors:  Cécile Borel; Sébastien Lamy; Gisèle Compaci; Christian Récher; Pauline Jeanneau; Jean Claude Nogaro; Eric Bauvin; Fabien Despas; Cyrille Delpierre; Guy Laurent
Journal:  BMC Cancer       Date:  2015-04-15       Impact factor: 4.430

7.  Dose intensity analysis in advanced ovarian cancer patients.

Authors:  V Torri; E L Korn; R Simon
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.